SCHEMBL20203879

SCHEMBL20203879

FC(F)(F)C(F)(F)c1nnc2ccc(Cl)nn12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.75
KDM4E B2RXH2 4/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
GAA P10253 1/20 0.50
DYRK1A Q13627 2/20 0.43
DYRK2 Q92630 2/20 0.43
HTT P42858 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP1A2 P05177 2/20 0.39
SCN5A Q14524 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
DYRK1B Q9Y463 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750158 0.86 ALDH1A1 (1.00) ALDH1A1KDM4ESMN1; SMN2DYRK1ADYRK2
SCHEMBL2265102 0.84 KDM4E (1.00) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL22744857 0.83 ALDH1A1 (0.75) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL2267586 0.83 ALDH1A1 (0.75) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL12910694 0.79 MEN1 (0.54) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL24616729 0.79 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL2268505 0.79 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL6631672 0.79 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL7225078 0.72 ALDH1A1 (0.59) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL612506 0.71 KDM4E (1.00) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 US disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 US disclosed
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ALDH1A1 916/4885KDM4E 2066/4885SMN1; SMN2 334/4885
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ALDH1A1 916/4885KDM4E 2066/4885SMN1; SMN2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.